Free Trial

Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives $30.62 Average Price Target from Analysts

Travere Therapeutics logo with Medical background
Remove Ads

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the fourteen research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $30.62.

Several analysts have recently weighed in on the stock. Citigroup raised their price objective on shares of Travere Therapeutics from $31.00 to $35.00 and gave the stock a "buy" rating in a report on Monday, February 24th. Evercore ISI raised their price objective on shares of Travere Therapeutics from $33.00 to $45.00 and gave the stock an "outperform" rating in a report on Wednesday, February 12th. JPMorgan Chase & Co. raised their price objective on shares of Travere Therapeutics from $42.00 to $44.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Travere Therapeutics in a report on Friday, February 21st. Finally, Canaccord Genuity Group raised their price objective on shares of Travere Therapeutics from $22.00 to $45.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th.

Check Out Our Latest Research Report on Travere Therapeutics

Travere Therapeutics Price Performance

TVTX traded up $0.60 during midday trading on Friday, reaching $19.73. 1,137,210 shares of the company's stock were exchanged, compared to its average volume of 1,411,373. The firm has a market capitalization of $1.75 billion, a price-to-earnings ratio of -4.81 and a beta of 0.75. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. Travere Therapeutics has a one year low of $5.12 and a one year high of $25.29. The business has a 50-day simple moving average of $20.33 and a two-hundred day simple moving average of $17.71.

Remove Ads

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.15). The business had revenue of $74.79 million for the quarter, compared to the consensus estimate of $72.38 million. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. As a group, research analysts predict that Travere Therapeutics will post -1.4 EPS for the current year.

Insider Buying and Selling at Travere Therapeutics

In other Travere Therapeutics news, CAO Sandra Calvin sold 15,000 shares of the firm's stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $17.22, for a total value of $258,300.00. Following the transaction, the chief accounting officer now directly owns 54,927 shares of the company's stock, valued at approximately $945,842.94. This trade represents a 21.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP William E. Rote sold 5,200 shares of the firm's stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $23.53, for a total transaction of $122,356.00. Following the completion of the transaction, the senior vice president now directly owns 98,519 shares in the company, valued at approximately $2,318,152.07. The trade was a 5.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 206,335 shares of company stock valued at $4,453,012. 3.75% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Travere Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Entropy Technologies LP bought a new position in shares of Travere Therapeutics during the fourth quarter worth $214,000. Aigen Investment Management LP bought a new position in shares of Travere Therapeutics during the third quarter worth $170,000. Oppenheimer & Co. Inc. bought a new position in shares of Travere Therapeutics during the third quarter worth $673,000. US Bancorp DE boosted its position in shares of Travere Therapeutics by 323.4% during the fourth quarter. US Bancorp DE now owns 31,795 shares of the company's stock worth $554,000 after purchasing an additional 24,286 shares in the last quarter. Finally, FMR LLC boosted its position in shares of Travere Therapeutics by 27.5% during the third quarter. FMR LLC now owns 147,416 shares of the company's stock worth $2,062,000 after purchasing an additional 31,772 shares in the last quarter.

About Travere Therapeutics

(Get Free Report

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Featured Stories

Analyst Recommendations for Travere Therapeutics (NASDAQ:TVTX)

Should You Invest $1,000 in Travere Therapeutics Right Now?

Before you consider Travere Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.

While Travere Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads